PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Cancer Research0 citations

Evaluating EP0031 as Monotherapy and with Chemotherapy in Advanced RET-Fusion-Positive NSCLC

Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJaime RubioEGElena GarraldaBBBenjamin Besse

Discussion

Loading...

Member takes

Overview

Phase I/II trial evaluates EP0031’s effectiveness in advanced RET-fusion-positive NSCLC, suggesting a potential combined treatment approach.

Key Points

  • The study aims to assess the safety and efficacy of EP0031, a selective RET inhibitor, both alone and in combination with chemotherapy in RET-fusion-positive NSCLC.
  • Ongoing phase I/II trial recruiting patients with advanced RET-fusion-positive NSCLC.
  • Monotherapy RP2D of EP0031 determined at 90 mg daily with chemotherapy cohorts receiving standard doses for four cycles.
  • Endpoints include tumor response by RECIST v1.1, progression-free survival, overall survival, safety, and pharmacokinetics.
  • EP0031 showed activity in patients previously untreated with selective RET inhibitors.
  • Synergy confirmed between EP0031 and chemotherapy in preclinical studies.
  • Ongoing monitoring of safety and incidence of dose-limiting toxicities during combination treatment.

Cite This Study

Rubio et al. (2026) studied this question.

synapsesocial.com/papers/69e47376010ef96374d8f453https://doi.org/10.1158/1538-7445.am2026-ct213
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.2024 · 2 citations
  2. 2Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced RET fusion–positive non–small cell lung cancer (NSCLC).2026 · 1 citations
  3. 3Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.2026
  4. 4Abstract CT056: Development of a novel next-generation RET inhibitor2024
  5. 5Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study.2024 · 4 citations